scholarly journals Response to the Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease

2020 ◽  
Vol 3 (2) ◽  
pp. 96-97
Author(s):  
Ken Bassett ◽  
Vijaya Musini
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Position Statement ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Canadian Association ◽  
Inflammatory Bowel

Tu1883 Activation of the Nuclear Receptor FXR by Oral Chenodeoxycholic Acid in Patients With Crohn's Colitis: Potential Therapeutic Consequences for Inflammatory Bowel Disease

2012 ◽  
Vol 142 (5) ◽  
pp. S-869 ◽  
Author(s):  
Fiona D. van Schaik ◽  
Raffaella Maria Gadaleta ◽  
Frank G. Schaap ◽  
Saskia W. van Mil ◽  
Peter D. Siersema ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Nuclear Receptor ◽  
Chenodeoxycholic Acid ◽  
Bowel Disease ◽  
Crohn’S Colitis ◽  
Therapeutic Consequences ◽  
Crohn's Colitis ◽  
Inflammatory Bowel

scholarly journals Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia

2019 ◽  
Vol 49 (7) ◽  
pp. 859-866 ◽  
Author(s):  
Wayne Massuger ◽  
Gregory T. C. Moore ◽  
Jane M. Andrews ◽  
Monique F. Kilkenny ◽  
Megan Reyneke ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Quality Of Care ◽  
Bowel Disease ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Inflammatory Bowel

M1146 The Ontario Crohn's & Colitis Cohort: Validation of An Algorithm to Identify Children Diagnosed with Inflammatory Bowel Disease Using Health Administrative Data

2009 ◽  
Vol 136 (5) ◽  
pp. A-359-A-360
Author(s):  
Eric I. Benchimol ◽  
Astrid Guttmann ◽  
Anne M. Griffiths ◽  
Linda Rabeneck ◽  
David R. Mack ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Administrative Data ◽  
Bowel Disease ◽  
Health Administrative Data ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Inflammatory Bowel

scholarly journals Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

2006 ◽  
Vol 13 (6) ◽  
pp. 655-660 ◽  
Author(s):  
Troy D. Jaskowski ◽  
Christine M. Litwin ◽  
Harry R. Hill
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Immunoglobulin A ◽  
General Term ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Iga Antibody ◽  
Inflammatory Bowel ◽  
Positive Results ◽  
Good Agreement

ABSTRACT Inflammatory bowel disease (IBD) is the general term used for a heterogeneous group of intestinal disorders, including Crohn's disease (CD) and ulcerative colitis (UC). Serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of CD and UC. Immunoglobulin A (IgA) antibody directed against the outer membrane protein C (OmpC) of Escherichia coli is said by one group to have clinical utility in diagnosing IBD, specifically in ASCA-negative CD patients. Our objective in this study was to compare the results obtained from two separate laboratories offering similar IBD tests using sera from suspected IBD patients. One hundred ninety-seven sera received for IBD testing were included in the study. The agreement between the two laboratories was 93.4% for ASCA IgA, 90.9% for ASCA IgG, and 87.8% for atypical pANCA IgG. There were 25 sera with ASCA-negative/OmpC-positive results reported by one laboratory. Thirteen of these 25 (52.0%) ASCA-negative/OmpC-positive sera were also atypical pANCA positive (9 as determined by both laboratories, 3 by one, and 1 by the other). Atypical pANCA antibody is found primarily in IBD patients with UC and colon-limited CD (Crohn's colitis). We conclude that the ASCA and atypical pANCA assays showed good agreement between the two laboratories, but the data for ASCA-negative/OmpC-positive sera suggest that many (52.0%) of these patients were more likely to have had UC or Crohn's colitis based on the presence of an atypical pANCA.

scholarly journals Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease

2014 ◽  
Vol 28 (7) ◽  
pp. 371-372 ◽  
Author(s):  
John K Marshall ◽  
Anthony R Otley ◽  
Waqqas Afif ◽  
Charles N Bernstein ◽  
Lawrence Hookey ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Position Statement ◽  
Canadian Association ◽  
Inflammatory Bowel

scholarly journals Corrigendum to The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation

2020 ◽  
Vol 26 (7) ◽  
pp. 1118-1118
Author(s):  
K T Park ◽  
Orna G Ehrlich ◽  
John I Allen ◽  
Perry Meadows ◽  
Eva M Szigethy ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Inflammatory Bowel ◽  
The Cost

Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease

2020 ◽  
Vol 55 (12) ◽  
pp. 1419-1426
Author(s):  
Krupa Krishnaprasad ◽  
Alissa Walsh ◽  
Jakob Begun ◽  
Sally Bell ◽  
David Carter ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Management ◽  
Management Software ◽  
Crohn’S Colitis ◽  
Crohn's Colitis ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document